SEQUENCE LISTING

```
<110> CHAIN, Daniel G.
```

<120> RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS, DNA ENCODING AND METHODS OF USE THEREOF

<130> CHAIN1B

<140> 00

<141> 1999-10-12

<150> PCT/US98/06900

<151> 1998-04-09

<150> 60/041,850

<151> 1997-04-09

<160> 8

<170> PatentIn Ver. 2.0

<210> 1

<211> 59

<212> PRT

<213> Homo sapiens

<400> 1

Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val 1 5 10 15

His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
20 25 30

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Val
35 40 45

Ile Val Ile Thr Leu Val Met Leu Lys Lys Lys 50 55

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: HUMAN PEPTIDE

WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE

```
<400> 2
Asp Ala Glu Phe Arg Cys
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
      WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE
<400> 3
Asp Ala Glu Phe Arg His Asp Cys
  1
                  5
<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
      WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE
<400> 4
Cys Leu Met Val Gly Gly Val Val
<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
      WITH ARTIFICIAL TERMINAL CYSTEINE RESIDUE
<400> 5
Cys. Val Gly Gly Val Val Ile Ala
```

```
<210> 6
<211> 6
<212> PRT
<213> Homo sapiens
<400> 6
Asp Ala Glu Phe Arg His
<210> 7
<211> 13
<212> PRT
<213> Homo sapiens
<400> 7
Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe Arg His
                  5
                                      10
<210> 8
<211> 4
<212> PRT
<213> Homo sapiens
<400> 8
Glu Phe Arg His
  1
```

```
<210>9
<211>6
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400>9
Glu Val His His Gln Cys
               5
<210> 10
<211>12
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400> 10
Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
                                   10
<210>11
<211>8
<212> PRT
<213> Artificial Sequence>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400> 11
Cys-Gly-Gly-Val-Val-Ile-Ala-Thr
1
                 5
```

1

```
<210>12
<211>14
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400> 12
Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
1
                                    10
<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence>
<220>
<223> Description of Artificial Sequence: HUMAN PEPTIDE
<400>
```

Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr

10

```
and the party that the control of th
```

```
<210>9
     <211>6
     <212> PRT
     <213> Artificial Sequence>
     <220>
     <223> Description of Artificial Sequence: HUMAN PEPTIDE
     <400>9
     Glu Val His His Gln Cys
                    5
10
     1
     <210>10
     <211>12
     <212> PRT
     <213> Artificial Sequence>
     <223> Description of Artificial Sequence: HUMAN PEPTIDE
     <400> 10
20
     Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln
                      5
                                        10
     1
     <210> 11
25
     <211>8
     <212> PRT
     <213> Artificial Sequence>
     <220>
     <223> Description of Artificial Sequence: HUMAN PEPTIDE
30
     <400> 11
     Cys-Gly-Gly-Val-Val-Ile-Ala-Thr
                      5
```

<210> 12 <211> 14 <212> PRT <213> Artificial Sequence> <220> <223> Description of Artificial Sequence: HUMAN PEPTIDE <400> 12 Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val10 10 5 <210> 13 <211> 14 15 <212> PRT <213> Artificial Sequence> <220> <223> Description of Artificial Sequence: HUMAN PEPTIDE <400> 20 Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr

5

. .

10

1 10 00 1